Indiana University Health Plans Inc.

Eli Lilly Commits $40 Million to Indiana University for AI-Enhanced Clinical Trial Infrastructure

- Eli Lilly and Company will provide up to $40 million to Indiana University over five years to expand clinical trial access and create an AI-enabled clinical trial infrastructure focused on Alzheimer's disease, diabetes, cancer, and cell and gene therapy. - The partnership aims to enhance clinical trial design, improve patient recruitment, and boost operational efficiency while leveraging IU Health's extensive provider network and expanding to additional health systems across Indiana. - The collaboration will accelerate access to neurological health resources with an initial focus on Alzheimer's disease, building on IU's neuroscience strengths and Lilly's global leadership in Alzheimer's innovation. - The initiative seeks to cultivate skilled talent for Indiana's $99 billion life sciences sector through co-developed programs that will prepare students for careers in biotechnology and pharmaceutical research.